ORKA-002

Asset

Targets IL-17A and IL-17F to inhibit inflammatory signaling.

Stage: Preclinical
Modality: Antibody
Target: IL17A; 2
Indications: 0
Trials: 1
Developer

Indications

2

Plaque psoriasis
Preclinical, sec.gov, Apr 3, 2024
Psoriatic arthritis
Preclinical, sec.gov, Apr 3, 2024

In the full profile

Targets and what it contains2
Owner and partners2
Evidence for its targets2
Competitors10
Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.